Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Stefanie Hammer

Hans-Georg Lerchen

Anne-Sophie Rebstock

Beatrix Stelte-Ludwig

Lisa Dietz

Sandra Berndt

Stephan Märsch

Simone Greven

Christoph Mahlert

Dennis Kirchhoff

Anette Sommer

Yolanda Cancho Grande

Sven Wittrock

Uwe Gritzan

Ernst Weber

Mark Trautwein

Christian Votsmeier

Dorian Schönfeld

Nikolaus Pawlowski

Julian Marius Glück

Patrick Jones

Jenny Fitting

The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases.

Antibody drug conjugates (ADCs) having enzymatically cleavable groups

Antibody drug conjugates (ADCS) having enzymatically cleavable groups

Specific binder-drug conjugates (ADCs) of kinesin spindle protein inhibitors, effective metabolites of these ADCs, processes for preparing these ADCs, the use of these ADCs for the treatment and/or prevention of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases, are described.

Specific antibody drug conjugates (ADCs) having KSP inhibitors

The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.

Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies

Growing community of inventors

Berlin, Germany

Stefanie Hammer